Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-IL13, 13C5.5 Vector   (CAT#: GTVCR-WQ43MR)

This product GTVCR-WQ43MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting IL13. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Humanized
RefSeq NM_001354991.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-IL13, 13C5.5 Vector (GTVCR-WQ43MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2020MR IVTScrip™ pT7-VEE-mRNA-Anti-CD19, MOR-00208 Vector Vector MOR-00208
GTVCR-WQ186MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF10B, ABBV-621 Vector Vector ABBV-621
GTVCR-WQ802MR IVTScrip™ pSP6-VEE-mRNA-Anti-SOST, BPS-804 Vector Vector BPS-804
GTVCR-WQ2080MR IVTScrip™ pT7-VEE-mRNA-Anti-IFNG, NI-0501 Vector Vector NI-0501
GTVCR-WQ1640MR IVTScrip™ pT7-VEE-mRNA-Anti-PCSK9, JS002 Vector Vector JS002
GTVCR-WQ2614MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF13C, VAY-736 Vector Vector VAY-736
GTVCR-WQ821MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD3E&MS4A1, BTCT4465A Vector Vector BTCT4465A
GTVCR-WQ343MR IVTScrip™ pT7-VEE-mRNA-Anti-INSR, AGT-181 Vector Vector AGT-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW